Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
biochemistry, genetics and molecular biology
Prognostic importance of c-erbB-2 expression in breast cancer
Journal of Clinical Oncology, Volume 10, No. 7, Year 1992
Notification
URL copied to clipboard!
Description
Purpose: To evaluate the prognostic importance of immunocytochemically determined c-erbB-2 overexpression in the primary tumors of patients with breast cancer. Patients and Methods: Primary tumors from 1,506 breast cancer patients (760 node-negative and 746 node-positive) who were treated in the International (Ludwig) Breast Cancer Study Group Trial V were studied. Node-negative patients were allocated randomly to either a single cycle of perioperative chemotherapy (PeCT) or no adjuvant treatment, and node-positive patients received either a prolonged chemotherapy (with tamoxifen for postmenopausal patients) or a single perioperative cycle. Results: Tumors from 16% of the node-negative patients and 19% of the node-positive patients were found to be c-erbB-2-positive. In both groups c-erbB-2 positivity correlated with negative progesterone receptors (PR), negative estrogen receptors (ER), and high tumor grade. Lobular carcinomas were all negative, and, thus support the view that such tumors represent a defined subtype of breast carcinoma. The expression of c-erbB-2 was prog-nostically significant for node-positive but not for node-negative patients. However, in both subgroups, the prognostic significance was greater for patients who had received more adjuvant therapy. For node-positive patients, the effect of prolonged-duration therapy on disease-free survival (DFS) was greater for patients without c-erbB-2 overexpression (hazards ratio [HR], = 0.57; 95% confidence interval [Cl], 0.46 to 0.72) than for those with c-erbB-2 overexpression (HR, 0.77; 95% Cl, 0.51 to 1.16). Similarly, for node-negative patients, the effect of PeCT on DFS was greater for those without c-erbB-2 overexpression (HR, 0.82; 95% Cl, 0.61 to 1.09) than for those with c-erbB-2 overexpression (HR, 1.22; 95% Cl, 0.66 to 2.25). Conclusion: We conclude that tumors with overexpression of the c-erbB-2 oncogene are less responsive to cyclophosphamide, methotrexate, and fluorouracil (CMF)-containing adjuvant therapy regimens than those with a normal amount of gene product. © 1992 by American Society of Clinical Oncology.
Authors & Co-Authors
Gusterson, Barry A.
Unknown Affiliation
Gelber, Richard D.
Unknown Affiliation
Goldhirsch, Aaron
Unknown Affiliation
Price, Karen N.
Unknown Affiliation
Rudenstam, Carl Magnus
Unknown Affiliation
Golouh, Rastko
Unknown Affiliation
Reed, Richard G.
Unknown Affiliation
Tiltman, Andrew John
Unknown Affiliation
Torhorst, Joachim K.H.
Unknown Affiliation
Grigolato, Piergiovanni
Unknown Affiliation
Bettelheim, Radka M.
Unknown Affiliation
Neville, Alexander Munro
Unknown Affiliation
Castiglione, Monica M.
Unknown Affiliation
Collins, John Paxton
Unknown Affiliation
Lindtner, Jurij
Unknown Affiliation
Statistics
Citations: 848
Authors: 15
Identifiers
ISSN:
0732183X
Research Areas
Cancer
Genetics And Genomics